site design templates

Privacy Policy


This study complied with the principles of the Declaration of Helsinki and Korean and was reviewed and approved by the Institutional Review Board of Korea Institute for Skin and Clinical Sciences (Seoul, Republic of Korea).

A total of 20 female volunteers (age, 30–65) were selected on the basis of predetermined inclusion and exclusion criteria. Inclusion criteria were as follows: Volunteers were female and >30 years old; subjects voluntarily signed the informed consent form; subjects were healthy without acute or chronic physical diseases, including any skin diseases; and subjects were available for follow-up during the testing period. A person with any of the following factors was excluded from the study: Pregnant, breast feeding or potentially pregnant; person who had been treated with any external application containing steroids for a skin disease treatment for >1 month; had participated in the a similar test within the last 6 months; person with sensitive or hypersensitive skin; person with skin abnormality on the test site, including moles, acne, erythema, and dilated capillaries; person who received any treatment on the test area within the last 6 months. Participants were withdrawn for the following reasons and these were reported: Adverse events, such as itching or erythema at the test area; hindrance of the evaluation due to a medical treatment, application of another product, excessive sun exposure, or excessive drinking or smoking during the test period; inability to participate in a follow-up appointment during the test period due to personal reasons; and person who did not comply with the study directions without specific reason.

Adverse events, including erythema, edema, scaling, itching, stinging, burning, tightness, prickling and other abnormalities, were visually examined and described on the case report form at every visit. The records included the degree of symptoms and whether these were mild, moderate or severe. Each subject's attendance was also recorded. Whether the participant was excluded from the study due to withdrawal was also noted. If a subject was unable to continue in the study, she signed an abandonment consent form.

Preparation and application of test materials

The facial cream and eye cream were freshly prepared for this study. The facial cream contains 1% palmitoyl oligopeptide and palmitoyl tetrapeptide-7 (BulkActives, Keelung City, Taiwan), 1% S. marianum seed oil (Botanic Innovations LLC, Spooner, WI, USA), 1% vitamin E (BulkActives), 1% xylitylglucoside, xylitol, and anhydroxylitol (Seppic S.A., Puteaux, France), 1% Rosmarinus officinalis leaf extracts (Flavex Naturextrakte GmbH, Rehlingen-Siersburg, Germany), 3% jojoba oil (Biocosmethic, Bonnelles, France), 3% avocado oil (Biocosmethic) and 1% squalane (BulkActives). The eye cream contains 1% palmitoyl oligopeptide and palmitoyl tetrapeptide-7 (BulkActives), 1% hesperidin methyl chalcon, dipeptide-2 (Sederma, Le Perray-en-Yvelines, France), 1% S. marianum seed oil (Botanic Innovations LLC), 1% Hordeum vulgare extracts (Presperse Corporation, Somerset, NJ, USA), 1% sodium hyaluronate (Jinwoo Bio, Inc., Seoul, Republic of Korea), 1% glycosphingolipid (Wha Costech Inc., Gyeonggi-Do, Seoul, Republic of Korea), 1% vitamin E (BulkActives), 3% jojoba oil (Biocosmethic), 1% jojoba esters (International Flora Technologies, Ltd., Chandler, AZ, USA), 1% squalane (BulkActives) and 1% acacia wax (Hangzhou Reb Technology Co., Ltd., Hangzhou, China).

Following facial washing, subjects applied the eye cream around eyes and face cream on the facial area twice per day, morning and night. Except for the test materials supplied by the institution, subjects were prohibited from using other products that may affect the results during the trial period. These other products included eye cream, functional cosmetics against aging and treatments such as masks or massages.

Evaluation of wrinkle improvement

All clinical analyses were conducted after cleansing face with same cleanser (Cleansing Foam; Anna Holtz Skin Care, Incheon, Republic of Korea) and resting in a controlled temperature and humidity room (temperature, 22±1°C; humidity, 45±5%) for 30 min. All measurements were conducted prior to any test material application and subsequently after 2 and 4 weeks of application.

For evaluation of wrinkle improvement, a PRIMOS Lite 3D Face and Skin Scanner Analyzing System (GFMesstechnik GmbH, Berlin, Germany) was utilized. The outer corner of the right eye was measured three consecutive times with the PRIMOS Lite after placing subjects' face onto a special PRIMOS face-held-equipment (GFMesstechnik GmbH) and focusing the outer corner of eye on a same pattern of the PRIMOS Lite to prevent the test area from moving. The images adjusted to the same position each time by applying 3D matching and were analyzed with the PRIMOS Lite software (version 5.6E; GFMesstechnik GmbH). The measurement variable Ra (average of all heights and depths to the reference plane) was used for wrinkle analysis as the most common surface roughness index worldwide, which represents the maximal mathematical average of the profile within the entire measurement range. The Ra value decreases with a lower depth of wrinkles, indicating that skin wrinkles were improved.

Evaluation of skin elasticity improvement

For evaluation of skin elasticity improvement, the DermaLab USB elasticity probe (Cortex Technology ApS, Hadsund, Denmark) was applied. After attaching the probe to the skin with tape, the left cheek under the eye was measured only once for prevention of skin fatigue caused by repeated measurement. The DermaLab USB elasticity probe quantifies skin changes and restoring forces in accordance with inhalation of skin and the duration of the inhalation, and the results were analyzed using DermaLab USB analysis software, version 1.09 (Cortex Technology ApS). Young's modulus (E) was used for elasticity analysis, which is the value representing the difference in forces to raise surface skin as much as 1.5 mm, the distance between two infrared sensing wires within the probe. Its unit of measure is the mega pascal (MPa). Young's modulus (E) increases with a higher elasticity, indicating that skin elasticity was improved.

Evaluation of dermal density improvement

For evaluation of dermal density improvement, an ultrasonographic DUB® SkinScanner (Tpm Taberna Pro Medicum GmbH, Lüneberg, Germany) was applied. After applying ultrasonography gel, 3 cm from the outer corner of left eye was measured by using the probe at a right angle with skin and pressing skin with same pressure. The range of analysis was set in limits from epidermis to upper subcutaneous fat layer. The value increases with a higher density of dermis, indicating that dermal density was improved.

Evaluation of skin tone improvement

For evaluation of skin tone improvement, a CR-2600D spectrophotometer (Konica Minolta, Inc., Tokyo, Japan) was used. The right cheek was measured three consecutive times, and the average value was determined. The L* and a* of three measurement values were determined as a measure of skin tone. L* indicates brightness, a* indicates red and b* indicates yellow.

Evaluation of abnormal skin response

During the trial period, medical doctors (Dr Kyu Joong Ahn and Dr Hyung Jin Hahn) determined using a visual inspection whether subjects had any visual dermatological side-effects (including erythema, edema and scaling) or not. We indicated the degree of symptoms and reported the results. A survey was conducted to ask subjects about abnormal skin responses.

Statistical analysis

The data were analyzed using paired t-tests with SPSS 17.0 software for Windows (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant result.